Archives

FORUS Therapeutics Inc Announces Health Canada Approval of BESREMI® (ropeginterferon alfa-2b) for Polycythemia Vera (PV)

Jul 6, 2026

(OAKVILLE, Ontario) July 6, 2026 – FORUS Therapeutics Inc (“FORUS”), a wholly owned subsidiary of PharmaEssentia Corp, is pleased to announce that it has received a Notice of Compliance (NOC) authorizing BESREMI® (ropeginterferon alfa-2b) for the treatment of adults...

Accessibility by WAH

FORUS Therapeutics Inc Announces Health Canada Approval of BESREMI® (ropeginterferon alfa-2b) for Polycythemia Vera (PV)

Recent Posts

Recent Comments

Categories

Meta